Literature DB >> 17166804

Peripheral nervous system involvement in patients with cancer.

Jean-Christophe Antoine1, Jean-Philippe Camdessanché.   

Abstract

Involvement of the peripheral nervous system (PNS) is common in patients with cancer and any part, including motor neurons, sensory ganglia, nerve roots, plexuses, cranial and peripheral nerves, and neuromuscular junctions, can be affected. Different mechanisms can initiate damage associated with cancer-related PNS disorders. These include tumour infiltration, toxicity of treatments, metabolic and nutritional perturbations, cachexia, virus infections, and paraneoplastic neurological syndromes. The type of cancer, lymphoma, or solid tumour is a further determinant of a PNS disorder. In this Review we discuss the different causes and mechanisms of disorders of the PNS in patients with cancer and we will focus on their assessment and diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17166804     DOI: 10.1016/S1474-4422(06)70679-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  24 in total

1.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

Review 2.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

Review 3.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 4.  Exercise intervention studies in patients with peripheral neuropathy: a systematic review.

Authors:  Fiona Streckmann; Eva M Zopf; Helmar C Lehmann; Kathrin May; Julia Rizza; Philipp Zimmer; Albert Gollhofer; Wilhelm Bloch; Freerk T Baumann
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

5.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

6.  Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy.

Authors:  Mehdi Saad; Dimitri Psimaras; Camille Tafani; Magali Sallansonnet-Froment; Jean-Henri Calvet; Alice Vilier; Jean-Marie Tigaud; Flavie Bompaire; Marie Lebouteux; Thierry de Greslan; Bernard Ceccaldi; Jean-Michel Poirier; François-Régis Ferrand; Sylvestre Le Moulec; Olivier Huillard; François Goldwasser; Hervé Taillia; Thierry Maisonobe; Damien Ricard
Journal:  J Neurooncol       Date:  2016-01-09       Impact factor: 4.130

7.  Incidence and spectrum of paraneoplastic neurological syndromes: single center study.

Authors:  Meena A Kanikannan; Y Sirisha; Megha S Uppin; Sheik A Jabeen; Rukmini M Kandadai; Challa Sundaram; Digumarti Raghunadharao; Rupam Borgohain
Journal:  J Neurooncol       Date:  2015-08-27       Impact factor: 4.130

8.  Treatment options in paraneoplastic disorders of the peripheral nervous system.

Authors:  Jean-Christophe Antoine; Jean-Philippe Camdessanché
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

9.  Runx2 was Correlated with Neurite Outgrowth and Schwann Cell Differentiation, Migration After Sciatic Nerve Crush.

Authors:  Dazhi Ding; Peipei Zhang; Yuxi Liu; Yi Wang; Weiwei Sun; Zhaohui Yu; Zhen Cheng; Youhua Wang
Journal:  Neurochem Res       Date:  2018-10-29       Impact factor: 3.996

10.  Stepwise approach to myopathy in systemic disease.

Authors:  Jasvinder Chawla
Journal:  Front Neurol       Date:  2011-08-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.